File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Excessive mortality in 1,353 five-year survivors of nasopharyngeal cancer

TitleExcessive mortality in 1,353 five-year survivors of nasopharyngeal cancer
Authors
Issue Date2020
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
American Society of Clinical Oncology (ASCO) 56th Annual Meeting, Virtual meeting, Chicago, USA, 29 May - 02 June 2020. In Journal of Clinical Oncology, 2020, v. 38 n. 15, Suppl., abstract no. e24090 How to Cite?
AbstractBackground: Survival of NPC patients has improved in past decades. Yet, survivors continue to face elevated risks of life-threatening late effects. Their impact on late mortality remains poorly quantified. Methods: 1353 five-year NPC survivors diagnosed between 1997 and 2013 at Queen Mary Hospital were reviewed. Their demographics and treatment data were taken from electronic medical records. Survival probability, standardized mortality ratios (SMRs) and absolute excessive risk were calculated for overall and cause-specific deaths. Results: At median follow-up time of 12.4 years, 412 (30.5%) five-year survivors had died at the time of analysis. 66.2% of deaths attributed to non-recurrence death. Estimated 10-, 15-, and 20-year survival probability were 81.4%, 67.6%, and 57.3% respectively. Compared to Hong Kong general population, absolute excessive risk of death from any causes was 17 deaths per 1000 person-years; overall SMR was 3.52 (95% CI: 3.19 to 3.87, p<0.001). Increases in cause-specific mortality were seen for death due to pulmonary (SMR: 6.75; 95% CI: 5.67 to 7.98) and secondary malignancy (SMR: 1.41; 95% CI: 1.06 to 1.83). Conclusions: Five-year NPC survivors still face excessive mortality long after diagnosis, and majority of death was from non-recurrence death. Further analyses are needed to determine predictive factors of excessive mortality.
Description2020 ASCO Annual Meeting I - Session: Symptoms and Survivorship: Late and Long-Term Effects - Abstract #:e24090
Persistent Identifierhttp://hdl.handle.net/10722/291039
ISSN
2021 Impact Factor: 50.717
2020 SCImago Journal Rankings: 10.482
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChiang, CL-
dc.contributor.authorCheung, CL-
dc.contributor.authorHingley, JP-
dc.contributor.authorSing, CW-
dc.contributor.authorFong, KS-
dc.contributor.authorLam, TC-
dc.contributor.authorLee, VHF-
dc.contributor.authorAu, KH-
dc.contributor.authorChow, JCH-
dc.contributor.authorCheung, YT-
dc.contributor.authorNgan, KCR-
dc.contributor.authorChoi, CW-
dc.contributor.authorLee, AWM-
dc.contributor.authorWong, ICK-
dc.date.accessioned2020-11-02T05:50:42Z-
dc.date.available2020-11-02T05:50:42Z-
dc.date.issued2020-
dc.identifier.citationAmerican Society of Clinical Oncology (ASCO) 56th Annual Meeting, Virtual meeting, Chicago, USA, 29 May - 02 June 2020. In Journal of Clinical Oncology, 2020, v. 38 n. 15, Suppl., abstract no. e24090-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/291039-
dc.description2020 ASCO Annual Meeting I - Session: Symptoms and Survivorship: Late and Long-Term Effects - Abstract #:e24090-
dc.description.abstractBackground: Survival of NPC patients has improved in past decades. Yet, survivors continue to face elevated risks of life-threatening late effects. Their impact on late mortality remains poorly quantified. Methods: 1353 five-year NPC survivors diagnosed between 1997 and 2013 at Queen Mary Hospital were reviewed. Their demographics and treatment data were taken from electronic medical records. Survival probability, standardized mortality ratios (SMRs) and absolute excessive risk were calculated for overall and cause-specific deaths. Results: At median follow-up time of 12.4 years, 412 (30.5%) five-year survivors had died at the time of analysis. 66.2% of deaths attributed to non-recurrence death. Estimated 10-, 15-, and 20-year survival probability were 81.4%, 67.6%, and 57.3% respectively. Compared to Hong Kong general population, absolute excessive risk of death from any causes was 17 deaths per 1000 person-years; overall SMR was 3.52 (95% CI: 3.19 to 3.87, p<0.001). Increases in cause-specific mortality were seen for death due to pulmonary (SMR: 6.75; 95% CI: 5.67 to 7.98) and secondary malignancy (SMR: 1.41; 95% CI: 1.06 to 1.83). Conclusions: Five-year NPC survivors still face excessive mortality long after diagnosis, and majority of death was from non-recurrence death. Further analyses are needed to determine predictive factors of excessive mortality.-
dc.languageeng-
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncology-
dc.relation.ispartof56th Annual Meeting of the American Society Of Clinical Oncology (ASCO 2020)-
dc.titleExcessive mortality in 1,353 five-year survivors of nasopharyngeal cancer-
dc.typeConference_Paper-
dc.identifier.emailChiang, CL: chiangcl@hku.hk-
dc.identifier.emailCheung, CL: lung1212@hku.hk-
dc.identifier.emailSing, CW: wingsing@hku.hk-
dc.identifier.emailLam, TC: lamtc03@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailNgan, KCR: rkcngan@hku.hk-
dc.identifier.emailChoi, CW: hcchoi@hku.hk-
dc.identifier.emailLee, AWM: awmlee@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChiang, CL=rp02241-
dc.identifier.authorityCheung, CL=rp01749-
dc.identifier.authorityLam, TC=rp02128-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityNgan, KCR=rp02371-
dc.identifier.authorityLee, AWM=rp02056-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.natureabstract-
dc.identifier.doi10.1200/JCO.2020.38.15_suppl.e24090-
dc.identifier.hkuros317813-
dc.identifier.volume38-
dc.identifier.issue15, Suppl.-
dc.identifier.spageabstract no. e24090-
dc.identifier.epageabstract no. e24090-
dc.identifier.isiWOS:000560368308506-
dc.publisher.placeUnited States-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats